HK2 and liver cancer: We chose to use liver cancer cell lines to investigate HK2 as a therapeutic target because of (i) the substantial contributions of both HK1−HK2+ and HK1+HK2+ tumor cell lines to the liver CCLE population, (ii) the lack of effective treatment for liver cancers, and (iii) the prediction of liver cancer as the third most lethal cancer in the USA in the next decade [17].